Dr. Dan Roden ANDREW F. HOLMES DEAN OF
MEDICINE DISTINCTION LECTURES

Dr. Dan Roden

Professor of Medicine, Pharmacology, and Biomedical Informatics
Director, Oates Institute for Experimental Therapeutics,
Senior Vice President for Personalized Medicine
Vanderbilt University Medical Center

Functional Genomics and Translational Biology Medal of Honor
from the American Heart Association

Rawls Palmer Progress in Medicine Award
from the American Society for Clinical Pharmacology and Therapeutics

Distinguished Scientist Award and the Douglas Zipes lectureship
from the Heart Rhythm Society

Title

Using Little Data and Big Data to Personalize Medicine

When

Wednesday, April 19, 2017
4:30 to 6:00 p.m.

Where

Redpath Museum Auditorium
859 Sherbrooke Street West, Montréal, QC
Dan Roden was born and raised in Montreal, received the BSc and MDCM degrees from McGill University, and trained in Internal Medicine at the Royal Victoria Hospital. He then went to Vanderbilt University where, after fellowships in Clinical Pharmacology and Cardiology, he joined the faculty and has remained there since. His initial career focus – that he has maintained – was studies of the clinical, genetic, cellular, and molecular basis of arrhythmia susceptibility and variability responses to arrhythmia therapies. Over the last 10 years, Dr. Roden has led Vanderbilt’s broader efforts in pharmacogenomics discovery and implementation. He is principal investigator for the Vanderbilt sites of the National Institutes of Health’s Pharmacogenomics Research Network (PGRN) and the National Human Genome Research Institute’s Electronic Medical Records and Genomics (eMERGE) Network. He directs the Vanderbilt DNA databank BioVU, a discovery resource that as of early 2017 included >230,000 samples linked to deidentified electronic medical records. He is a leader in Vanderbilt’s PREDICT project that since 2010 has been preemptively embedded pharmacogenomic variant data in the electronic medical records of >14,000 Vanderbilt patients.

Dr. Roden served as director of the Division of Clinical Pharmacology (1992-2004), and in 2006 was named to lead Vanderbilt’s efforts in Personalized Medicine. He has received the Leon Goldberg Young Investigator Award and the Rawls-Palmer Progress in Medicine Award from the American Society for Clinical Pharmacology and Therapeutics; the Distinguished Scientist Award and the Douglas Zipes lectureship from the Heart Rhythm Society; and the Distinguished Scientist Award and the inaugural Functional Genomics and Translational Biology Medal of Honor from the American Heart Association. He currently serves on the Advisory Council to the National Human Genome Research Institute and the Science Board of the FDA. He has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians, and fellowship in the American Association for the Advancement of Science.